Lapanix 250 MG (Lapatinib)
Product Name : Lapanix(Lapatinib)
Generic Name : Lapatinib
Formulation : Tablet
Available Pack Size : 150’s Pot
Available Strengths : 250 mg
Registrations : 08.07.2021
Product Information
Lapanix 250 MG (Lapatinib) is a potent, orally bioavailable, reversible dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER2) tyrosine kinases a first-in-class small-molecule agent in the 4-anilinoquinazoline chemical class approved for the treatment of HER2-positive advanced or metastatic breast cancer. Lapanix is indicated in combination with capecitabine for patients who have progressed after prior anthracycline, taxane, and trastuzumab therapy, and in combination with letrozole for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. It works by binding to the intracellular ATP-binding domains of both EGFR (ErbB1) and HER2 (ErbB2) simultaneously, blocking receptor autophosphorylation and shutting down the downstream RAS/MAPK and PI3K/AKT signalling cascades that drive HER2-amplified tumour proliferation, survival, and metastatic spread. For the complete range of oncology and specialty cancer medicines available through Mediaid Pharmacy, including combination agents and other targeted breast cancer therapies, visit the oncology medicines portfolio. Lapanix is manufactured by Beacon Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Lapanix 250 MG (Lapatinib)
| Brand Name | Lapanix (Lapatinib) |
| Generic Name | Lapatinib INN (as Lapatinib Ditosylate) |
| Drug Class | Dual ErbB1 (EGFR) and ErbB2 (HER2) Tyrosine Kinase Inhibitor 4-Anilinoquinazoline Class |
| Available Strength | 250 mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 150 Tablets per Pot |
| Primary Indications | HER2-positive advanced or metastatic breast cancer in combination with capecitabine (post-anthracycline, taxane, trastuzumab) or in combination with letrozole (hormone receptor-positive, HER2-positive metastatic breast cancer in postmenopausal women) |
| Regulatory Approvals | USFDA Approved (March 2007 capecitabine combination; 2010 letrozole combination). EMA Approved (Tyverb, 2008 capecitabine; 2010 letrozole combination). Health Canada Approved. |
| Originator Brand | Tykerb / Tyverb by GlaxoSmithKline / Novartis |
| Manufacturer | Beacon Pharmaceuticals Ltd., Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy Worldwide Shipping Available |
| Registration Date | 08/07/2021 |
| Storage Conditions | Store below 30°C in a dry place away from light and moisture. Keep out of the reach of children. |
How Lapanix 250 MG (Lapatinib) Works Dual ErbB1/ErbB2 Kinase Inhibition and HER2 Pathway Blockade
Lapatinib, the active ingredient in Lapanix 250 MG, belongs to the 4-anilinoquinazoline class of tyrosine kinase inhibitors. It is a potent, selective, and reversible dual inhibitor of ErbB1 (EGFR, HER1) and ErbB2 (HER2, HER2/neu) two closely related receptor tyrosine kinases in the ErbB/HER family that are overexpressed in approximately 20–25% of all breast cancers and strongly associated with aggressive tumour behaviour, resistance to endocrine therapy, and poor prognosis. In HER2-positive (HER2+) breast cancers, HER2 gene amplification drives constitutive receptor dimerisation and activation of the downstream RAS/MAPK and PI3K/AKT/mTOR signalling pathways, producing sustained oncogenic signals for tumour cell proliferation, survival, invasion, and angiogenesis.
Lapanix works by binding to the intracellular ATP-binding site of both ErbB1 and ErbB2 receptors simultaneously. This competitive ATP binding blocks receptor autophosphorylation the critical first step in downstream signal propagation and prevents activation of ERK-1, ERK-2, and AKT kinases. With IC50 values of 10.2 nM for EGFR (ErbB1) and 9.8 nM for ErbB2 (HER2), and more than 300-fold selectivity for ErbB1 and ErbB2 over other kinases including c-Src, c-Raf, MEK, CDK1, CDK2, p38, Tie-2, and VEGFR2, Lapatinib’s dual receptor blockade shuts down HER2-driven tumour signalling through both homodimeric (HER2:HER2) and heterodimeric (HER2:EGFR) receptor complexes. This dual blockade is mechanistically critical because HER2:EGFR heterodimers are the most potent signalling configurations in HER2-amplified tumours and cannot be inhibited by trastuzumab (which targets only the extracellular domain of HER2) or by EGFR-only inhibitors.
A key advantage of Lapanix over trastuzumab is its ability to overcome the p95-HER2 truncation resistance mechanism. In some HER2-positive tumours, proteolytic shedding of the HER2 extracellular domain generates p95-HER2 a constitutively active truncated fragment that lacks the trastuzumab binding site but retains the intracellular kinase domain. Because Lapanix binds the intracellular kinase domain rather than the extracellular domain, it remains fully active against p95-HER2-driven tumours that are resistant to trastuzumab. Additionally, lapatinib’s small-molecule oral structure allows penetration of the blood-brain barrier, giving it activity in CNS metastases a complication present in up to 30% of patients with HER2-positive metastatic breast cancer. Oncologists seeking a complete portfolio of targeted oncology medicines and specialty cancer treatments can review Mediaid Pharmacy’s full oncology medicines range.
Approved Indications for Lapanix 250 MG (Lapatinib)
Lapanix (Lapatinib) 250 MG is indicated for the following oncological conditions in adult patients:
|
HER2-Positive Advanced/Metastatic Breast Cancer + Capecitabine Lapanix 1,250 mg once daily (five 250 mg tablets) in combination with capecitabine 2,000 mg/m²/day (in two divided doses 12 hours apart on Days 1–14 of a 21-day cycle) for adult patients with advanced or metastatic HER2-positive breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab. This is the primary and most established indication, based on a Phase III trial in which lapatinib plus capecitabine prolonged time to progression (TTP) from 18.3 weeks (capecitabine alone) to 23.9 weeks (HR 0.72; 95% CI 0.56–0.92) and doubled the objective response rate from 17.4% to 31.4%. USFDA approved March 2007; EMA approved 2008. |
Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer + Letrozole Lapanix 1,500 mg once daily (six 250 mg tablets) in combination with letrozole 2.5 mg once daily for postmenopausal women with hormone receptor-positive (HR+), HER2-positive metastatic breast cancer for whom endocrine therapy is indicated. This indication was established by the EGF104900 and related studies, demonstrating that lapatinib plus letrozole significantly improved progression-free survival versus letrozole alone in the HR+/HER2+ double-positive population. USFDA and EMA approved 2010. |
|
HER2-Positive Metastatic Breast Cancer + Trastuzumab (Selected Markets) In selected regulatory jurisdictions, Lapanix is indicated in combination with trastuzumab for patients with hormone receptor-negative metastatic breast cancer overexpressing HER2 who have progressed on prior trastuzumab plus chemotherapy. The dual HER2 blockade of Lapatinib (intracellular kinase domain) plus trastuzumab (extracellular domain) addresses both trastuzumab-sensitive and p95-HER2-driven resistance, delivering complementary mechanisms of HER2 pathway suppression. |
HER2-Positive Metastatic Breast Cancer CNS Metastases Activity CNS metastases develop in up to 30% of patients with HER2-positive metastatic breast cancer and remain largely inaccessible to trastuzumab due to the blood-brain barrier. Lapatinib’s small-molecule oral structure enables blood-brain barrier penetration, and clinical evidence supports its activity in HER2-positive breast cancer brain metastases, either as monotherapy or in combination with capecitabine, in patients who develop CNS relapse after prior HER2-targeted therapy. |
Key Clinical Benefits of Lapanix (Lapatinib) 250 MG
|
Simultaneous Dual ErbB1 and ErbB2 Kinase Blockade Lapanix simultaneously inhibits both EGFR (ErbB1) and HER2 (ErbB2) at IC50 values of 10.2 nM and 9.8 nM respectively with greater than 300-fold selectivity over other kinases. This dual blockade suppresses all ErbB homodimeric and heterodimeric signalling complexes, including the most potent HER2:EGFR heterodimers that drive aggressive HER2-amplified breast cancer growth and that EGFR-only or HER2-only agents cannot fully suppress. |
Overcomes Trastuzumab Resistance via p95-HER2 By targeting the intracellular kinase domain rather than the extracellular binding domain, Lapanix remains fully active against p95-HER2 the constitutively active truncated HER2 fragment that arises from extracellular domain shedding and renders tumours resistant to trastuzumab. This mechanism makes Lapanix a critical option for patients progressing on trastuzumab-based regimens. |
Blood-Brain Barrier Penetration CNS Activity As a small-molecule oral agent, Lapanix penetrates the blood-brain barrier an advantage not shared by large-molecule biologics such as trastuzumab or pertuzumab. Clinical evidence supports Lapatinib’s activity in HER2-positive brain metastases, an increasingly critical consideration given that CNS relapse affects up to 30% of patients with HER2-positive metastatic breast cancer. |
|
Phase III Efficacy Doubled Response Rate vs Capecitabine Alone In the pivotal Phase III registration trial, Lapatinib plus capecitabine prolonged median time to progression from 18.3 to 23.9 weeks (HR 0.72; p=0.00023) and almost doubled the objective response rate from 17.4% to 31.4% versus capecitabine monotherapy forming the regulatory evidence base for its global approval in heavily pre-treated HER2-positive metastatic breast cancer. |
Convenient 150-Tablet Pot Uninterrupted Continuous Dosing The 150-tablet pot of Lapanix 250 mg provides a 30-day supply at the 1,250 mg/day capecitabine combination dose (five tablets daily) or a 25-day supply at the 1,500 mg/day letrozole combination dose (six tablets daily) supporting the continuous once-daily administration schedule that is essential for maintaining plasma drug concentrations above the IC50 threshold required for sustained HER2 pathway suppression. |
Affordable Generic Alternative to Tykerb / Tyverb Lapanix contains the same active ingredient as Tykerb/Tyverb (GlaxoSmithKline/Novartis) in the same 250 mg film-coated tablet form, manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards delivering the same proven dual ErbB1/ErbB2 inhibition at a significantly lower cost, making essential HER2-targeted breast cancer treatment accessible to patients worldwide. |
How to Take Lapanix 250 MG (Lapatinib) Dosage and Administration Guidelines
Route and Timing: Oral taken once daily as a single dose. Lapanix must be taken on an empty stomach, at least one hour before or at least one hour after a meal. Do not divide the daily dose. If a dose is missed, do not replace it; resume the next dose at the regularly scheduled time.
Combination with Capecitabine (HER2-positive advanced/metastatic breast cancer): 1,250 mg (five 250 mg tablets) once daily continuously. Capecitabine is given at 2,000 mg/m²/day in two divided doses 12 hours apart on Days 1–14 of each 21-day cycle. Note: capecitabine must be taken with food or within 30 minutes after eating the opposite food requirement to Lapanix.
Combination with Letrozole (HR+/HER2+ metastatic breast cancer): 1,500 mg (six 250 mg tablets) once daily continuously, together with letrozole 2.5 mg once daily. Treatment continues until disease progression or unacceptable toxicity occurs.
Dose Reduction for Cardiac Events: Discontinue Lapanix in patients with a confirmed decrease in Left Ventricular Ejection Fraction (LVEF) of Grade 3 or above, or LVEF that drops below the institution’s lower limit of normal. After a minimum of 2 weeks, if LVEF recovers to normal and the patient is asymptomatic, restart Lapanix at a reduced dose: 1,000 mg/day (capecitabine combination) or 1,250 mg/day (letrozole combination).
Dose Reduction for Diarrhoea: Grade 3 or above diarrhoea interrupt Lapanix. Restart at a reduced dose level once diarrhoea resolves to Grade 1 or below. Dose reduction levels: first reduction to 1,000 mg/day (capecitabine combination); second reduction to 750 mg/day; third discontinue.
Strong CYP3A4 Inhibitors: Reduce Lapanix dose to 500 mg once daily when co-administered with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, itraconazole, voriconazole, grapefruit juice). Allow a 1-week washout period before restoring the standard dose after the inhibitor is stopped. Avoid grapefruit, starfruit, Seville oranges, and their juices throughout treatment.
Strong CYP3A4 Inducers: Gradually up-titrate Lapanix from the standard dose based on tolerability when co-administered with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John’s Wort). Reduce back to the standard dose upon discontinuation of the inducer.
Severe Hepatic Impairment (Child-Pugh Class C Pre-existing): Reduce starting dose to 750 mg/day (capecitabine combination) or 1,000 mg/day (letrozole combination). If severe hepatic impairment develops during treatment, permanently discontinue Lapanix.
Renal Impairment: No dose adjustment required; renal elimination accounts for less than 2% of the excreted dose. Limited data are available in patients with severe renal impairment; exercise caution.
Clinical Monitoring Requirements During Lapanix (Lapatinib) Treatment
Comprehensive clinical monitoring is mandatory throughout Lapanix treatment. Cardiac function (LVEF) must be assessed at baseline by echocardiogram or MUGA scan to confirm it is within the institution’s normal limits, and re-evaluated periodically during treatment. LVEF declines occur in a majority of cases within the first 12 weeks of treatment. Liver function tests (LFTs) including ALT, AST, alkaline phosphatase, and total bilirubin must be checked before treatment initiation and every 4 to 6 weeks during therapy; severe hepatotoxicity, including fatal cases, has been reported. QTc interval should be assessed at baseline using 12-lead ECG in patients at risk of QT prolongation (e.g., hypokalaemia, hypomagnesaemia, congenital long QT syndrome, concurrent QT-prolonging agents), as Lapatinib is associated with concentration-dependent QTc prolongation and rare cases of Torsades de Pointes, ventricular fibrillation, cardiac arrest, and sudden death. Electrolytes (serum potassium and magnesium) must be corrected before and maintained during Lapanix treatment. Patients should be monitored for clinical signs of diarrhoea (onset often within the first days of treatment), dermatological toxicity (rash, nail changes), and interstitial lung disease or pneumonitis which may be severe and require dose interruption or permanent discontinuation.
Drug Interactions and Important Safety Information for Lapanix (Lapatinib)
Lapatinib is a substrate of hepatic CYP3A4 and CYP2C8 enzymes, and is itself an inhibitor of CYP3A4, CYP2C8, and P-glycoprotein (ABCB1). This dual substrate/inhibitor profile creates a clinically significant interaction landscape. Strong CYP3A4 inhibitors including clarithromycin, ketoconazole, itraconazole, voriconazole, nefazodone, and grapefruit products substantially increase Lapatinib plasma exposure; reduce the Lapanix dose to 500 mg once daily when co-administration is unavoidable. Strong CYP3A4 inducers including rifampin, carbamazepine, phenytoin, phenobarbital, dexamethasone, and St. John’s Wort markedly reduce Lapatinib plasma concentrations and clinical efficacy; avoid co-administration whenever possible.
Because Lapatinib inhibits CYP3A4, CYP2C8, and P-gp, it is likely to increase the plasma exposure of concomitantly administered drugs that are substrates of these pathways including certain statins, immunosuppressants, anticoagulants, and other cancer medicines. Drugs known to prolong the QTc interval must be used with particular caution. Patients must declare all current medications, supplements, herbal products, and dietary habits especially grapefruit, starfruit, and Seville orange consumption to their treating oncologist before beginning Lapanix therapy.
Side Effects and Precautions of Lapanix (Lapatinib)
|
Common Side Effects (≥20% Incidence) Diarrhoea the most common adverse effect; often early onset, may be severe and require antidiarrhoeals (e.g., loperamide) and fluid/electrolyte replacement Rash (acneiform / maculopapular) patients should use SPF ≥30 sunscreen and limit sun exposure Nausea Fatigue Vomiting Palmar-Plantar Erythrodysaesthesia (Hand-Foot Syndrome) more common when combined with capecitabine Decreased appetite and weight loss Stomatitis and mucosal inflammation Alopecia Nail disorders and dry skin |
Serious Warnings and Precautions Cardiotoxicity (LVEF decrease) decreases in LVEF reported, with a majority of cases within the first 12 weeks. May progress to symptomatic cardiac failure. Confirm baseline LVEF before starting and monitor throughout. Discontinue and consider restart at reduced dose after recovery to normal LVEF. Hepatotoxicity (Boxed Warning) severe hepatotoxicity, including fatal cases, has occurred. Monitor LFTs before treatment and every 4–6 weeks. Permanently discontinue if severe liver function changes occur. Do not restart. QTc interval prolongation concentration-dependent. Correct hypokalaemia and hypomagnesaemia before starting. Avoid concomitant QT-prolonging drugs. Rare cases of Torsades de Pointes, ventricular fibrillation, cardiac arrest, and sudden death reported. Interstitial lung disease (ILD) and pneumonitis may be severe or fatal. Discontinue Lapanix in patients with Grade 3 or above ILD or pneumonitis. Not recommended during pregnancy or breastfeeding. Use effective contraception during treatment and for at least one week after the final dose. Lapatinib may impair male fertility. Patients aged 65 and above appear to have a higher incidence of oedema and earlier onset of cardiac toxicity monitor closely in elderly patients. Hypersensitivity reactions including anaphylaxis contraindicated in patients with known severe hypersensitivity to Lapatinib or any excipient. |
Who Should Use Lapanix 250 MG (Lapatinib)?
Lapanix is indicated for adult oncology patients with confirmed HER2-positive (HER2-overexpressing or HER2-gene-amplified) advanced or metastatic breast cancer. HER2 status must be confirmed by validated testing methods (IHC 3+ or FISH/ISH amplified) before initiating treatment, as patients with HER2-negative status derive no benefit. In combination with capecitabine, Lapanix is prescribed for patients who have progressed after at least one prior line of therapy containing an anthracycline, a taxane, and trastuzumab in the metastatic setting. In combination with letrozole, it is prescribed for postmenopausal women with HR-positive, HER2-positive metastatic breast cancer who are candidates for endocrine therapy. Lapanix must be prescribed and supervised by a qualified medical oncologist experienced in advanced breast cancer and targeted systemic therapy. A mandatory pre-treatment assessment including cardiac function (LVEF), liver function tests (LFTs), ECG, serum electrolytes, and HER2 status confirmation is required before initiating Lapanix therapy. Oncologists managing breast cancer patients requiring comprehensive access to oncology and targeted cancer medicines including HER2-targeted agents, combination chemotherapy partners, and other specialty oncology treatments can review Mediaid Pharmacy’s full oncology medicines portfolio for availability and worldwide supply.
Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh
Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh and the number one oncology and specialty medicine company in the country. Beacon was the first company in Bangladesh to export cancer drugs and currently exports to markets across Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards. Lapanix (Lapatinib) 250 MG is one of Beacon’s core oncology products, offering a high-quality, bioequivalent, and affordable alternative to Tykerb/Tyverb (GlaxoSmithKline/Novartis) at a fraction of the originator cost. Every batch of Lapanix exported by Beacon meets the quality, purity, and bioequivalence requirements validated for international supply to regulated markets worldwide.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Lapanix (Lapatinib)
Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted cancer therapy medications. Lapanix (Lapatinib) 250 MG is available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Europe, and beyond. Our team provides full order support including pricing, availability confirmation, export documentation, and delivery tracking for oncologists, hospitals, cancer centres, and patients requiring Lapanix internationally. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for enquiries about pricing and delivery to your country.
Why Choose Lapanix (Lapatinib) from Mediaid Pharmacy?
Lapanix 250 MG represents a clinically proven, mechanistically differentiated option in the treatment of HER2-positive advanced and metastatic breast cancer. As the generic bioequivalent of Tykerb/Tyverb (GlaxoSmithKline/Novartis), Lapanix delivers the same active ingredient Lapatinib with the same unique dual ErbB1 and ErbB2 kinase inhibition profile at a dramatically more affordable price. Its ability to overcome p95-HER2-mediated trastuzumab resistance, penetrate the blood-brain barrier, and suppress all HER2-driven signalling complexes including the most potent HER2:EGFR heterodimers distinguishes it from monoclonal antibody-based HER2-targeted therapies and makes it a critical component of multi-line HER2-positive breast cancer management. Manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy with worldwide shipping, Lapanix gives oncologists and patients worldwide access to essential HER2-targeted therapy without the financial barrier of brand-name pricing. For the full range of oncology medicines including combination partners (capecitabine, letrozole, trastuzumab) and other HER2-targeted and specialty cancer treatments, visit Mediaid Pharmacy’s oncology medicines portfolio.
Frequently Asked Questions About Lapanix 250 MG (Lapatinib)
What is Lapanix 250 MG (Lapatinib) used for?
Lapanix 250 MG (Lapatinib) is a dual ErbB1 (EGFR) and ErbB2 (HER2) tyrosine kinase inhibitor used for HER2-positive advanced or metastatic breast cancer. It is indicated in combination with capecitabine for patients who have progressed after prior therapy with anthracyclines, taxanes, and trastuzumab, and in combination with letrozole for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. By simultaneously blocking both ErbB1 and ErbB2 at the intracellular kinase domain, Lapanix suppresses the HER2-driven proliferation and survival signalling that drives this aggressive breast cancer subtype.
What is the correct dose of Lapanix (Lapatinib)?
The dose of Lapanix depends on the combination regimen. In combination with capecitabine, the dose is 1,250 mg (five 250 mg tablets) once daily continuously. In combination with letrozole, the dose is 1,500 mg (six 250 mg tablets) once daily continuously. In both cases, Lapanix must be taken on an empty stomach, at least one hour before or one hour after any meal. Do not split the daily dose into multiple administrations. Dose reductions to 1,000 mg/day and 750 mg/day are used to manage cardiac events, hepatotoxicity, diarrhoea, or CYP3A4 drug interactions. Always follow your prescribing oncologist’s exact instructions.
What strength and pack size is Lapanix (Lapatinib) available in?
Lapanix is available as 250 mg film-coated tablets in a pot of 150 tablets. This pack size provides a 30-day supply at the 1,250 mg/day capecitabine combination dose (five tablets per day) and supports uninterrupted continuous once-daily treatment which is essential for maintaining therapeutic plasma Lapatinib concentrations above the IC50 threshold for sustained ErbB1 and ErbB2 inhibition.
Is Lapanix the same as Tykerb (Lapatinib by GlaxoSmithKline/Novartis)?
Yes. Lapanix is the generic equivalent of Tykerb (also marketed as Tyverb). Both products contain the same active ingredient Lapatinib ditosylate in the same 250 mg film-coated tablet form. Lapanix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh under WHO-GMP-certified conditions and delivers the same dual ErbB1 and ErbB2 kinase inhibition as Tykerb, at a significantly lower cost making essential HER2-targeted breast cancer treatment more financially accessible to patients worldwide.
What are the most common side effects of Lapanix (Lapatinib)?
The most common side effects of Lapanix (occurring in more than 20% of patients) include diarrhoea, rash, nausea, fatigue, vomiting, decreased appetite, palmar-plantar erythrodysaesthesia (hand-foot syndrome), and stomatitis. Serious risks include cardiotoxicity (LVEF decrease), severe hepatotoxicity (including fatal cases), QTc prolongation, interstitial lung disease, and hypersensitivity reactions. Always consult your prescribing oncologist for a complete individual risk-benefit assessment before and during Lapanix treatment.
Can Lapanix (Lapatinib) be used with capecitabine, letrozole, or trastuzumab?
Yes. Lapanix is specifically approved in combination with capecitabine (at 1,250 mg/day) or with letrozole (at 1,500 mg/day). In selected markets it is also indicated with trastuzumab for hormone receptor-negative HER2-positive metastatic breast cancer after prior trastuzumab plus chemotherapy. These combinations leverage Lapanix’s intracellular kinase domain blockade alongside chemotherapy, endocrine, or monoclonal antibody mechanisms for additive or synergistic anti-tumour activity. Avoid combining Lapanix with drugs that strongly inhibit or induce CYP3A4 unless dose adjustments are made.
Is Lapanix (Lapatinib) safe during pregnancy or breastfeeding?
No. Lapanix is not recommended during pregnancy or breastfeeding due to potential harm to the foetus and nursing infant. Women of childbearing potential must use effective contraception during treatment and for at least one week after the final dose. Lapatinib may also impair male fertility. Consult your oncologist before starting Lapanix if you are pregnant, planning to become pregnant, or currently breastfeeding.
Can I order Lapanix 250 MG (Lapatinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Lapanix (Lapatinib) 250 MG to patients, oncologists, hospitals, and healthcare facilities globally with worldwide shipping. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or send your enquiry to info@mediaidpharmacy.com for pricing, stock availability, export documentation, and delivery details for your country.
Order Lapanix 250 MG (Lapatinib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
